Overview

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Blood Cancer Research Partnership
Janssen Pharmaceuticals
Multiple Myeloma Research Consortium
The Leukemia and Lymphoma Society

Treatments:

Antibodies
Antibodies, Monoclonal
Daratumumab